UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 12, 2022
Regulus Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-35670 | 26-4738379 | ||
(State of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
4224 Campus Point Court, Suite 210 San Diego, CA | 92121 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 202-6300
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading | Name of each exchange | ||
Common Stock, par value $0.001 per share | RGLS | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On July 12, 2022, Regulus Therapeutics Inc. (the “Company”) received notification from Sanofi of its decision to terminate the Phase 2 clinical study of lademirsen (RG-012) for the treatment of Alport syndrome (the “HERA study”) for failure to meet Sanofi’s pre-defined futility criteria. Sanofi also notified the Company that it is currently evaluating different opportunities with respect to RG-012.
Under the terms of the Second Amended and Restated License and Collaboration Agreement dated February 4, 2014 between Sanofi and the Company, as amended (the “Agreement”), the Company had been eligible to receive a $25.0 million milestone in the event of successful completion of the HERA study. Under the Agreement, the Company will remain eligible for the milestone in the event of successful completion of a Phase 2 fibrosis proof of concept study.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Regulus Therapeutics Inc. | ||||||
Date: July 15, 2022 | By: | /s/ Joseph Hagan | ||||
Joseph Hagan | ||||||
President and Chief Executive Officer |